Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOPRANO
ISRCTN13282459Phase 2Recruiting
- Sponsor
- The Institute of Cancer Research
- Start
- Aug 2024
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of niraparib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by The Institute of Cancer Research. Primary endpoint: Progression-free survival. Started Aug 2024; status: recruiting.
02
Drugs
niraparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ISRCTN13282459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN13282459.